Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly's biggest catalyst at the moment comes from its hit weight loss medications, Mounjaro and Zepbound. Lilly is investing billions of dollars to scale manufacturing efforts as demand for ...

Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity star Zepbound. With the FDA’s green light on Friday, Lilly’s dual ...

Eli Lilly sells one of the most sought-after types of drugs today: weight loss drugs. The company’s Zepbound and Mounjaro have brought in blockbuster revenue, and more growth could be on the ...

Earnings Report 1.900 USD Q4 2021 Earnings Release 02/03/2022 Indices Commodities Currencies Stocks ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters. In a study sponsored by Lilly ...

Eli Lilly and Company (NYSE:LLY) investors who chased the stock toward its July/August 2024 highs have likely been stunned into submission as LLY has dropped into a bear market. As a result ...